Acadia Pharmaceuticals achieved a significant milestone in 2025, surpassing $1 billion in annual revenue. Despite a non-recurring $20 million IRA rebate adjustment that impacted GAAP figures, the company saw strong underlying volume growth for NUPLAZID and double-digit growth for DAYBUE. Net income was significantly bolstered by a $250 million non-cash income tax benefit.

Acadia Pharmaceuticals delivered a strong third quarter in 2025, with total revenues reaching $278.6 million, an 11% increase year-over-year. Both NUPLAZID and DAYBUE achieved significant sales growth, driven by increased prescriptions and expanded patient reach. The company also reported a net income of $71.8 million, or $0.42 per diluted share, benefiting from a tax benefit related to the One Big Beautiful Bill Act.

Acadia Pharmaceuticals delivered a strong second quarter in 2025, with total revenues reaching $264.6 million, a 9% increase year-over-year. Both NUPLAZID and DAYBUE showed significant sales growth, contributing to the positive financial performance. The company also highlighted progress in its R&D pipeline and key patent litigation wins.

Acadia Pharmaceuticals reported a strong start to 2025 with total revenues of $244.3 million in the first quarter, representing a 19% year-over-year increase. Both NUPLAZID and DAYBUE product sales contributed to the growth, with NUPLAZID sales up 23% and DAYBUE sales up 11%. The company also highlighted progress in its pipeline, accelerating the timeline for the COMPASS PWS Phase 3 study results.

Acadia Pharmaceuticals closed 2024 with record revenues for both NUPLAZID and DAYBUE in the fourth quarter, contributing to a 32% revenue growth for the full year. The company reported a net income of $143.7 million for Q4 2024, a significant increase from the previous year, and provided strong revenue guidance for 2025.

Acadia Pharmaceuticals reported a successful third quarter in 2024, with total revenues of $250.4 million, reflecting an 18% increase year-over-year. The company is on track to achieve over $1 billion in annualized sales in 2025, driven by the growth of NUPLAZID and DAYBUE.

Acadia Pharmaceuticals announced a successful second quarter in 2024, marked by a 46% year-over-year increase in total net product sales, driven by growth in both NUPLAZID and DAYBUE sales. The company is also progressing with its Phase 3 trial in Prader-Willi syndrome and Phase 2/Phase 3 program in Alzheimer’s disease psychosis.

Acadia Pharmaceuticals reported net product sales of $205.8 million, representing 74% revenue growth year over year, driven by DAYBUE and NUPLAZID.

Acadia Pharmaceuticals reported a transformational year in 2023, achieving 40% revenue growth driven by the launch of DAYBUE and growth in the NUPLAZID franchise. In the fourth quarter, the company advanced its pipeline with the initiation of Phase 3 and Phase 2 trials and reported net income of $45.8 million.

Acadia Pharmaceuticals reported record product revenue in Q3 2023, driven by the successful launch of DAYBUE and continued growth of NUPLAZID. The company is also advancing its late-stage pipeline with planned initiations of Phase 3 and Phase 2/Phase 3 studies for ACP-101 and ACP-204, respectively.

Acadia Pharmaceuticals reported a net income of $1.1 million for the second quarter of 2023, driven by strong performances from both the DAYBUE and NUPLAZID franchises. Total net product sales were $165.2 million, with NUPLAZID contributing $142.0 million and DAYBUE contributing $23.2 million.

Acadia Pharmaceuticals reported its Q1 2023 financial results, featuring the FDA approval and launch of DAYBUE for Rett syndrome and NUPLAZID net sales of $118.5 million, a 3% increase compared to Q1 2022. The company is also advancing its pipeline, including the completion of Phase 1 development for ACP-204 and nearing enrollment completion for the Phase 3 program for pimavanserin.

Acadia Pharmaceuticals reported Q4 2022 results, featuring NUPLAZID net sales of $136.5 million, a 4% increase from Q4 2021. The company's net loss for the quarter was $41.7 million, or $0.26 per share. The company is preparing for a transformative year in 2023 with potential FDA approval of trofinetide and advancement of its pipeline programs.

Acadia Pharmaceuticals reported Q3 2022 financial results with NUPLAZID net sales of $130.7 million. The company's trofinetide NDA for Rett syndrome was accepted for filing by the FDA.

Acadia Pharmaceuticals reported a 17% increase in NUPLAZID net sales compared to Q2 2021. The company submitted an NDA for trofinetide for Rett syndrome and is well-positioned for long-term growth with a strong balance sheet and a focus on strategic business development.

Acadia Pharmaceuticals reported first quarter 2022 financial results, with NUPLAZID net sales increasing by 8% compared to the first quarter of 2021. The company is focused on preparing for the upcoming Advisory Committee meeting for pimavanserin in Alzheimer's disease psychosis and the NDA submission for trofinetide in Rett syndrome.

Acadia Pharmaceuticals reported a net sales increase of 10% year over year, driven by growth in NUPLAZID prescriptions and market share. The company resubmitted its sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA and plans to submit an NDA for trofinetide for the treatment of Rett syndrome.

Acadia Pharmaceuticals reported Q3 2021 net sales of $131.6 million, a 9% increase over Q3 2020. The company is scheduled to meet with the FDA to discuss next steps towards a resubmission of the pimavanserin sNDA.

Acadia Pharmaceuticals reported a 5% increase in NUPLAZID net sales for Q2 2021, reaching $115.2 million. The company is engaging with the FDA regarding their DRP program and anticipates top-line results from Phase 3 Rett syndrome and Phase 2 postoperative pain studies by the end of the year. They reduced their full year revenue guidance to $480 to $515 million.

Acadia Pharmaceuticals reported a net sales increase for NUPLAZID in Q1 2021, reaching $106.6 million, an 18% increase compared to Q1 2020. The company is reiterating its full-year net sales guidance of $510 to $550 million. However, they also received Complete Response Letters from the FDA regarding their sNDA for NUPLAZID for dementia-related psychosis.

Acadia Pharmaceuticals reported strong financial results for Q4 2020, driven by robust sales of NUPLAZID. The company is focused on continued growth of NUPLAZID and the potential approval and launch of pimavanserin for dementia-related psychosis in 2021.

Acadia Pharmaceuticals reported net sales of NUPLAZID® of $120.6 million for the third quarter ended September 30, 2020, a 27% increase compared to $94.6 million for the same period in 2019. The company's net loss for the quarter was $84.7 million, or $0.54 per common share.

ACADIA Pharmaceuticals reported a net sales of $110.1 million for NUPLAZID in Q2 2020, a 32% increase compared to Q2 2019. The company updated its NUPLAZID net sales guidance for 2020 to $430 to $450 million.

ACADIA Pharmaceuticals reported a net sales increase of 43% for NUPLAZID in Q1 2020 compared to Q1 2019. The company is on track to submit a supplemental NDA for pimavanserin for the treatment of dementia-related psychosis this summer. Due to the anticipated COVID-19 impact, ACADIA reduced its 2020 revenue guidance by approximately 5%.

ACADIA Pharmaceuticals reported Q4 2019 net sales of NUPLAZID® were $98.3 million, an increase of 65% compared to Q4 2018. The company's net loss for the quarter was $53.0 million, or $0.34 per common share, compared to a net loss of $65.5 million, or $0.50 per common share, for the same period in 2018.